Upadacitinib Reduces Extraintestinal Manifestations of UC: Study

Researchers evaluated phase 3 data comparing the oral JAK inhibitor with placebo for treating anemia, peripheral arthropathy, axial arthropathy, and other extraintestinal manifestations.
Medscape Medical News

source https://www.medscape.com/viewarticle/969264?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?